Black Diamond Therapeutics IncQ) expected to post a loss of 25 cents a share - Earnings Preview
Black Diamond Therapeutics IncQ) is projected to report a loss of 25 cents per share for the quarter ending June 30, 2025, with no change in revenue. Analysts maintain a "buy" rating, with a median 12-month price target of $11.00, significantly above its last closing price of $2.66. The mean earnings estimate has dropped by 89.5% in the last three months. Previous quarterly performances have consistently beaten estimates.
- Black Diamond Therapeutics Inc (BDTX.OQ) (BDTX.O) is expected to
show no change in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025
- LSEG’s mean analyst estimate for Black Diamond Therapeutics Inc is for a loss of 25 cents per share.
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 5 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.”
- The mean earnings estimate of analysts had fallen by about 89.5% in the last three months.
- Wall Street’s median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.8% above its last closing price of $2.66 Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2025 0.49 0.02 0.98 Beat 4,511.
8
Dec. 31 2025 -0.31 -0.28 Beat 11
Sep. 30 2024 -0.38 -0.37 -0.28 Beat 25.1
Jun. 30 2024 -0.38 -0.39 -0.36 Beat 7
Mar. -0.42 -0.43 -0.35 Beat 19.5
31 2024
Dec. 31 2023 -0.45 -0.47 -0.34 Beat 27
Sep. 30 2023 -0.44 -0.49 -0.45 Beat 7.5
Jun. 30 2023 -0.54 -0.54 -0.52 Beat 3
This summary was machine generated August 1 at 13:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
